It is an honor to welcome you to the MPN/MDS Master Class, where leading experts and researchers come together to explore the latest advancements in
Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndrome (MDS).
This premier event, taking place on Saturday, October 4, 2025, at the Salwa Al Sabah Conference Center, Marina Hotel Kuwait,
is dedicated to deepening our understanding of these complex conditions. With insightful presentations from top specialists and interactive discussions,
we aim to foster collaboration and innovation in MPN and MDS research and care.
We are delighted to host the MPN/MDS Master Class, a unique opportunity focused on advancing knowledge, treatment,
and support for those affected by myeloproliferative neoplasms and myelodysplastic syndromes. Whether you are a clinician or researcher
this event offers invaluable insights and networking opportunities.
We look forward to your participation and support in making this master class a milestone event in the ongoing fight against MPNs and MDS.
Yours Sincerely, Chairperson
Dr.
Ahmad Alabdulkarim
Specialist Haematologist
Agenda Timeline
Agenda Timeline
Follow the session flow with our interactive agenda timelines.
Completed
Previous Session
π€
Ending Remarks
Sat, 04 Oct 2025 Β· 6:45 PM β 7:00 PM
Agenda
Agenda
08:30 - 09:00
Registration
09:00 - 09:15
MPN in Kuwait
Dr. Ahmad Alabdulkarim
SESSION I: Optimising MPN Diagnosis andΒ Management in 2025 and beyond Dr. Ahmad Alabdulkarim - Dr. Marwan Shaheen
09:15 - 09:35
Diagnostic Algorithms and genomic profiling in MPN: Emerging insights
Dr. Andrew Wilson
09:35 - 09:55
How best to approach the Cytopaenic Myelofibrosis Patient
Dr. Donal McLornan
09:55 - 10:15
Treatment Strategies in Essential Thrombocythaemia: time for a rethink
Dr.Β Andrew Wilson
10:15 - 10:35
Optimising management of Polycythaemia Vera in 2025
Dr. Samah Alimam
10:35 - 10:55
Symposium: Optimizing outcomes in MF
Dr. Fatima Khadada
10:55 - 11:10
Q & A
11:10 - 11:25
Coffee Break
SESSION II: Special Situations in MPN Dr. Ali Aljeraiwi - Dr. Ahmad Alhuraiji
11:25 - 11:45
Thrombosis challenges in MPN
Dr. Mohammed Alawadhy
11:45 - 12:05
Haemostasis challenges in MPN
Dr. Anwar Almasbahi
12:05 - 12:15
Prayer Break
12:15 - 12:35
Accelerated and Blast Phase MPN
Dr.Β Ahmad Alabdulkarim
12:35 - 12:55
How I treat MPN in pregnancy
Dr. Muna Alrasheed
12:55 - 13:15
Adolescents and Young Adults (AYA) with MPN: Optimising outcomes
Dr. Samah Alimam
13:15 - 13:30
Q & A
13:30 - 13:50
Opening Ceremony
13:50 - 14:45
Lunch Break
14:45 - 15:05
Syposium: JAKing The Right Path: Personalizing Myelofibrosis Management
Dr. Rami Komrokji
SESSION III: Rare MPN and MDS/MPN Overlap Dr. Mona Alrasheed - Dr. Taghreed Al Essa
15:05 - 15:25
Managing the unclassified: MPN-NOS and MPN/MDS-NOS. What should we do?
Dr. Donal McLornan
15:25 - 15:45
How I treat CMML: what's on the horizon?
Dr. Daniel Wiseman
15:45 - 16:05
Demystifying Hypereosinophilia Syndrome: Diagnosis, Challenges, and Treatment Advances
Dr. Jonathan Lambert
16:05 - 16:25
How I treat AdvancedΒ Systemic MastocytosisΒ in 2025
Dr. Jonathan Lambert
16:25 - 16:40
Q & A
16:40 - 16:55
Coffee Break
16:55 - 17:15
Symposium: Pacritinib in Practise: Real World Experience
Dr. Ayel Yahya
Dr. Mohammad Zureiqi
SESSION IV: MDS/AA
Dr. Fatima Khadada - Dr. Noura Alhashim
17:15 - 17:35
Classification and diagnosis of MDS : ICC versus WHO
Dr. Rami Komrokji
17:35 - 17:55
How I treat Low risk MDS in 2025 and beyond
Prof. Elspeth Payne
17:55 - 18:15
How I treat High Risk MDS in 2025 and beyond
Dr. Rami Komrokji
18:15 - 18:35
How I treat AA/Hypoplastic MDS
Prof. Elspeth Payne
18:35 - 18:45
Q & A
18:45 - 19:00
Ending Remarks
Our Speakers
Our Speakers
Meet the distinguished speakers joining us to share their expertise and insights at this event.
Dr. Ahmad Alabdulkarim
Specialist Haematologist at Jaber Alahmad Hospital Royal College of Surgeons Ireland - MD Kuwait Board of Haematology Clinical Fellowship in Myeloproliferative Neoplasms and Myelodysplastic syndromes - University College London Hospital Vice president of Kuwait Haematology Association Clinical Tutor in Kuwait Institute of Medical Specialisations
Dr. Andrew Wilson
Dr Wilson is a consultant haematologist at UCLH, specialising in the diagnosis and management of acute and chronic myeloid blood cancers, where he is also principal investigator for a number of clinical trials in MPNs and AML. He has a deep interest in education and training and is the clinical lead for education in the UCLH cancer division, vice-chair of the British Society for Haematology's education committee, and programme co-director for the UCL/Royal College of Physicians MSc in medical education.
Dr. Donal McLornan
Donal works as a consultant in the MPN, allogeneic transplant and CAR-T team at University College Hospital London, which has the largest combined transplant and cellular therapy program in the UK. He is the current chair of the Chronic Malignancy Working Party of the EBMT (MPN/MDS/CML/CLL/Plasma cell dyscrasia) and is co-chair of the EBMT scientific council. Additionally, he chairs the UK Blood Cancer Research Network MPN group. He has a particular interest in MPN, MDS/MPN overlap syndromes and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics.
Dr. Samah Alimam
Dr. Alimam is a Consultant Haematologist with extensive expertise in the diagnosis and management of blood cancers, general haematology, and transfusion medicine. She has a particular focus on myeloid disorders, especially myeloproliferative neoplasms (MPNs) and chronic myeloid leukaemia (CML). Dr. Alimam has a special clinical interest in the care of younger patients and the unique challenges of managing MPNs and CML during pregnancy. She is actively involved in clinical research at University College London Hospital, contributing to ongoing advancements in the field of haematology.
Dr. Fatima Khadada
Dr. Fatima Khadadah holds an FRCPC and ABIM in Internal Medicine and Hematology from the University of Toronto. She additionally completed a year in specialty leukemia training at the Princess Margaret Cancer Centre in Toronto in the fall of 2021. She then joined the staff of the Kuwait Cancer Centre where her clinical focus is on the care of people with acute and chronic leukemias such as MDS and MPN. She is a founding member and Treasurer of the Leukemia and Lymphoma Society of Kuwait. She is interested in post-graduate clinical education and is heavily involved in the Clinical Hematology Board in Kuwait. She is also currently completing an MSsCH in Community Health and Health Practitioner Education from the University of Toronto.
Dr. Mohammed Alawadhy
Clinical Hematologist at Mubarak Al Kabeer Hospital and Chairperson of its Thrombosis and Anticoagulation Committee. A University of Ottawa-trained Adult Thrombosis Fellow, and a clinical tutor at KIMS and Kuwait University.
Dr. Anwar Almasbahi
Dr. Anwar Almasbahi is a Hematology and Hemostasis Specialist at Jaber Al-Ahmad Hospital in Kuwait. She earned her Bachelor of Medicine and Bachelor of Surgery (M.B.B.Ch) from Kuwait University in 2013, obtained the Kuwaiti Board of Hematology (KBH) in 2019. She completed a Clinical Hemostasis Fellowship at the University of Toronto, Canada, in 2024. Her clinical focus is on the care of people with bleeding disorders, in addition to general benign hematology disorders.
Dr. Muna Alrasheed
Dr. Mona Alrasheed is a Consultant in Internal Medicine and Clinical Hematology. She completed her residency in Internal Medicine at the University of Toronto and her fellowship in Clinical Hematology at McMaster University. Dr. Al Rasheed earned her FRCPC and ABIM certifications in Internal Medicine in 2004 and in Clinical Hematology in 2006. She has been a Consultant in Clinical Hematology since 2010.
Dr. Rami Komrokji
Dr. Komrokji is the Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center, Tampa Florida. He is a senior Member of the Malignant Hematology and Experimental Therapeutics Program at Moffitt Cancer Center, and Professor in Medicine & Oncologic Services at the College of Medicine at the University of South Florida in Tampa, Florida. After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation. Dr. Komrokji is expert in myeloid neoplasms where he led several clinical trials and lectured worldwide. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and for Pacritinib in myelofibrosis. He has authored or co-authored more than 300 peer-reviewed manuscripts, 20 book chapters, and more than 1,000 abstracts in Hematologic Malignancies. He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and currently member of the NHLBI MDS natural history study steering committee and aplastic anemia and MDS foundation medical board of directors. He was member of the editorial board for Journal of Clinical Oncology (JCO). He is peer reviewer for several medical journals including Blood Journal, JCO and Leukemia Journal. He is a regularly invited speaker at national and international meetings and has won several awards in recognition of his work. Dr. Komrokji's research interests are in Phase I and II Clinical Trials and in the outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are myelodysplastic syndromes (MDS), Acutely Myeloid Leukemias, and Myeloproliferative neoplasms.
Dr. Daniel Wiseman
Dr Daniel Wiseman is a Senior Clinical Lecturer in the Division of Cancer Sciences, and an Honorary Consultant Haematologist at The Christie Hospital. His research interest is in mechanisms of myeloid leukaemogenesis, with particular focus on chronic myelomonocytic leukaemia and related myelodysplastic/myeloproliferative overlap neoplasms. Having completed a PhD in Tim Somervaille's lab in 2016, his postdoctoral research identified pathogenic collaboration between SRSF2 and IDH2 mutations in myeloid leukaemia development.
Since 2016 he has led the Oglesby CMML Research Programme in Manchester and was recently awarded a Cancer Research UK Advanced Clinician Scientist fellowship to further his work on splicing/epigenetic crosstalk in CMML. In the clinic he leads the Christie's MDS service, served as Translational Science lead for the UK NCRI MDS clinical studies group, and is chief investigator on several trials, including "AMMO": a UK multicentre phase 2 CMML investigator-initiated trial. He is also a member of the International Working Group for MDS/MPN.
Dr. Jonathan Lambert
Dr Jonathan Lambert is a consultant haematologist at University College London Hospitals (UCLH), with subspecialty expertise in myeloproliferative neoplasms (MPN) and lymphoma. He undertook his specialist training in haematology in London, based at UCLH, and completed a PhD in molecular haematology at the UCL Cancer Institute.
Dr Lambert sits on the MPN subgroup of the UK Blood Cancer Research Network and is involved in running numerous clinical studies at UCLH and nationally. He has published widely in peer-reviewed journals, and has been a co-author in a variety of national clinical guidelines as well as working as a clinical advisor to the UK NICE agency. He is currently Clinical Lead for the UCLH MPN service and the hospital's Clinical Digital Lead for Cancer.
Dr. Ayel Yahya
Dr. Mohammad Zureiqi
Prof. Elspeth Payne
Dr Payne is a Professor of Haematology at UCL Cancer Institute and Honorary Consultant haematologist at University College London Hospital. She trained in Internal Medicine in Glasgow and Oxford, and completed haematology training in London. After completing her medical training, she undertook her PhD at the Dana-Farber Cancer Institute in Boston, USA. Her research and clinical practice focuses on understanding the sequential events leading to the development of myelodyslasia or acute myeloid leukaemia and developing novel therapies for these conditions. She also leads the UK MDS Research Network and co-founded the Myeloid Cancer Prevention Network that seeks to develop clinical trials to treat and prevent myeloid disorders.
Scientific Committee
Scientific Committee
The Scientific Committee behind this event, ensuring academic quality and excellence.
Dr. Marwan Shaheen
Dr Marwan Shaheen is the Head of Chronic Leukemia and Myeloproliferative Neoplasms Section in the Department of Hematology, SCT and Cellular Therapy at King Faisal Specialist Hospital and Research Centre- Riyadh. He is also the Director of Long Term Follow-up program in Cancer Centre of Excellence. Dr Shaheen is certified Saudi Board of Internal Medicine and Adult Hematology then completed a fellowship in Adult Hematology and Bone Marrow Transplant at Princess Margaret Cancer Centre in Toronto, Canada. He was also the first certified Stem Cell Transplant Fellow from KFSH&RC.
Dr. Fatima Khadada
Dr. Fatima Khadadah holds an FRCPC and ABIM in Internal Medicine and Hematology from the University of Toronto. She additionally completed a year in specialty leukemia training at the Princess Margaret Cancer Centre in Toronto in the fall of 2021. She then joined the staff of the Kuwait Cancer Centre where her clinical focus is on the care of people with acute and chronic leukemias such as MDS and MPN. She is a founding member and Treasurer of the Leukemia and Lymphoma Society of Kuwait. She is interested in post-graduate clinical education and is heavily involved in the Clinical Hematology Board in Kuwait. She is also currently completing an MSsCH in Community Health and Health Practitioner Education from the University of Toronto.
Dr. Ahmad Alabdulkarim
Specialist Haematologist at Jaber Alahmad Hospital Royal College of Surgeons Ireland - MD Kuwait Board of Haematology Clinical Fellowship in Myeloproliferative Neoplasms and Myelodysplastic syndromes - University College London Hospital Vice president of Kuwait Haematology Association Clinical Tutor in Kuwait Institute of Medical Specialisations
Dr. Ali Aljeraiwi
MBBCh, Kuwait University 2010 Kuwait Board of Hematology (KIMS) 2018 MRCP (UK) 2019 Adult Thrombosis Medicine (uOttawa) 2021
Dr. Ahmad Alhuraiji
Ahmad Alhuraiji is a hemato-oncologist consultant working in the department of hematology at Kuwait Cancer Control Centre. His main focus of interest is the field of leukemia, myeloproliferative neoplasms, myelodysplastic syndrome and plasma cell disorders. He is involved in education and training of resident of the Kuwaiti hematology residency program and worked with other colleagues to establish the adult hematology clinical fellowship program in 2020.
Dr. Mona Alrasheed
Dr. Mona Al Rasheed is a Consultant in Internal Medicine and Clinical Hematology. She completed her residency in Internal Medicine at the University of Toronto and her fellowship in Clinical Hematology at McMaster University. Dr. Al Rasheed earned her FRCPC and ABIM certifications in Internal Medicine in 2004 and in Clinical Hematology in 2006. She has been a Consultant in Clinical Hematology since 2010.
Dr. Taghreed Al Eisa
Head of clinical hematology unit in AlJahra hospital and a member of Kuwait Institute for Medical Specialization (KIMS), mainly tutoring KBIM residents and a member in the MOH hemophilia committee.Deals with Benign and Malignant Hematological Disorders and first to establish specialised CML clinin in Kuwait.
Dr. Noura Alhashim
M.B.B.Ch β KU MRCP β UK Saudi fellowship of adult hematology - KFSH & RC - Consultant Hematologist &Internal medicine. - Head of Clinical Hematology unit at Mubarak AlKabeer Hospital β MOH, Kuwait. - Clinical tutor at facultyof medicine and Kuwait Institutes of medical specialties - KIMS
Dr. Ahmad Alsaffar
Dr. Ahmad AlSaffar is a Clinical Hematology specialist at Al-Sabah Hospital in Kuwait. He serves as the Chairperson of the Policy and Procedure Committee at the hospital and is the Secretary of the Kuwait Hematology Association. Dr. AlSaffar is also a Clinical Tutor at the Kuwait Institute for Medical Specializations (KIMS). A graduate of the University of Malta, he completed his residency in hematology through the Kuwait Board of Hematology. Dr. AlSaffar is actively involved in clinical practice, medical education, and health policy development.
Target Audience
Target Audience
This masterclass is designed for healthcare professionals, researchers, and specialists dedicated
to advancing hematology, oncology, and related disciplines.
Clinical Specialists
Hematologists
Medical Oncologists
Hematopathologists
Bone Marrow Transplant Physicians
Internal Medicine Physicians with Hematology Interest
Pediatric Hematologists
Radiation Oncologists
Obstetrician
Research & Academic
Clinical Researchers (MDs)
Geneticist
Technical & Support
Clinical Pharmacist
Lab Technician
Nurses
Conference Registration
Registration
Registration Deadline: 12:00 PM β SATURDAY, OCTOBER 4, 2025
Collaboration & Sponsorship
Collaboration
Sponsorship
Diamond
Silver
FAQ Section
Frequently Asked Questions
Registration Details
Please be sure to use a valid private email in the registration step.
Please be sure to write valid registration information.
Purchasing registration for multiple parties is not allowed.
Attendance Regulations
Physical Attendance: Please use the confirmed ticket sent to your registered email to get your ID from the registration desk.
CME Certificate & Regulations
In order to get the CME, please be sure that all of your data is correctly admitted through the registration process.
CME credits will be awarded to the target audience upon attending the event and scanning the QR code with our representative.
The certificate will be accessible post-event and will be sent to the email address provided during registration.
Payment Method & Refund Policy
We accept Knet and all major credit cards β VISA, Mastercard, Diners, AMEX etc.
Tickets purchased cannot be refunded for any reason.